GPT and type 2 diabetes mellitus: In the current analyses, we investigated the effects of empagliflozin on ALT and AST using several datasets collected in individuals with type 2 diabetes: the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease [15], pooled data from four Phase III trials [16–19] and a head-to-head trial of empagliflozin vs glimepiride [22].